Department of Rheumatology and Immunology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.
Centre of Neurological and Metabolic Research, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.
Front Endocrinol (Lausanne). 2022 Oct 13;13:1015516. doi: 10.3389/fendo.2022.1015516. eCollection 2022.
Rheumatoid arthritis (RA) is an autoimmune disorder. Multiple studies have investigated the risk of thyroid dysfunction in patients with RA but have reached conflicting conclusions. This systematic review aimed to determine whether patients with RA are at higher risk of thyroid dysfunction.
We comprehensively reviewed online literature databases, including PubMed, Scopus, Embase, and the Cochrane Library, from their respective inception dates to March 25, 2022. Studies that provided data on at least one case of thyroid dysfunction in RA patients and their controls were included. Based on these data, we calculated pooled odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) for thyroid dysfunction in RA and non-RA patients.
Twenty-nine studies met the inclusion criteria, involving a total of 35,708 patients with RA. The meta-analysis showed that, compared with non-RA patients, RA patients had an increased risk of developing thyroid dysfunction, particularly hypothyroidism (OR 2.25, 95% CI 1.78-2.84). Subgroup analysis suggested that study type and sample source of control group were the source of heterogeneity.
Patients with RA are at increased risk of developing thyroid dysfunction, especially hypothyroidism. Routine biochemical examination of thyroid function in RA patients should be strengthened. Larger prospective studies are needed to explore the causal relationship between RA and thyroid dysfunction, and to investigate the impact of thyroid dysfunction on RA disease activity, drug efficacy, and medication safety.
https://www.crd.york.ac.uk/prospero/, identifier CRD42022331142.
类风湿关节炎(RA)是一种自身免疫性疾病。多项研究调查了 RA 患者甲状腺功能障碍的风险,但得出了相互矛盾的结论。本系统评价旨在确定 RA 患者是否存在更高的甲状腺功能障碍风险。
我们全面检索了在线文献数据库,包括 PubMed、Scopus、Embase 和 Cochrane Library,检索时间从各数据库建库时间至 2022 年 3 月 25 日。纳入提供至少 1 例 RA 患者和对照者甲状腺功能障碍数据的研究。基于这些数据,我们计算了 RA 和非 RA 患者甲状腺功能障碍的汇总比值比(OR)及其相应的 95%置信区间(CI)。
29 项研究符合纳入标准,共纳入 35708 例 RA 患者。meta 分析显示,与非 RA 患者相比,RA 患者发生甲状腺功能障碍的风险增加,尤其是发生甲状腺功能减退症的风险(OR 2.25,95%CI 1.78-2.84)。亚组分析表明,研究类型和对照组的样本来源是异质性的来源。
RA 患者发生甲状腺功能障碍的风险增加,尤其是甲状腺功能减退症。应加强对 RA 患者甲状腺功能的常规生化检查。需要开展更大规模的前瞻性研究,以探讨 RA 与甲状腺功能障碍之间的因果关系,并研究甲状腺功能障碍对 RA 疾病活动、药物疗效和用药安全性的影响。
https://www.crd.york.ac.uk/prospero/,注册号 CRD42022331142。